Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb
Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

• Bristol-Myers Squibb recently reported strong second-quarter results, beating analyst expectations with earnings per share of $2.04 compared to a consensus estimate of $1.60, while revenue of $12.97 billion also exceeded forecasts, demonstrating robust operational performance and margin expansion.
• The company has significantly raised its full-year 2026 guidance, projecting adjusted earnings per share between $6.75 and $7.00, which is well above the previous consensus estimate of $6.31, signaling management confidence in continued growth and productivity initiatives.
• Bristol-Myers Squibb offers a compelling income opportunity with a dividend yield of 3.70%, supported by a sustainable payout ratio of 55.51%, making it an attractive option for investors seeking steady cash flow alongside potential capital appreciation.
• The stock is currently trading at $66.85, which is near its 52-week high of $68.64, reflecting strong market momentum and a breakout trend that has outperformed the broader healthcare sector over the past year.
• Institutional investors are increasing their stakes in the company, with major holders like Munich Reinsurance and BlackRock boosting their positions in the second quarter, indicating growing confidence in the firm's long-term strategic direction and portfolio renewal.